Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures

Johnson & Johnson's sales figures for Darzalex in the second quarter are so good that Genmab, which developed the drug, may increase its financial expectations for the year, says senior analyst Søren Løntoft Hansen.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT

Sydbank senior analyst Søren Løntoft Hansen expects Genmab to upgrade its total predicted market sales for 2021 after Johnson & Johnson's Q2 sales figures for Darzalex were revealed on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading